Krystal Biotech, Inc.

KRYS

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Dec 15, 2025

Drug Pipeline

Drug Name	Phase	Indication	Designations
Open Label Topical Beremagene Geperpavec (B-VEC)	Phase 3	Dystrophic Epidermolysis Bullosa	-
KB803	Phase 3	Dystrophic Epidermolysis Bullosa	-
KB707	Phase 2	Lung Cancer, Non-small Cell	-
Topical beremagene geperpavec	Phase 2	Dystrophic Epidermolysis Bullosa	-
Opdualag	Phase 2	Cancer	-
KB304	Phase 2	Wrinkles in Decolletage	-
KB801	Phase 2	Neurotrophic Keratitis	-

Catalyst Timeline

2 upcoming, 0 past

Phase 2Next

December 2025~KB801

Primary completion for KB801 trial (NCT06999733) in Neurotrophic Keratitis

⭐Phase 3

March 2026~KB803

Primary completion for KB803 trial (NCT07016750) in Dystrophic Epidermolysis Bullosa

Regulatory Approvals

KRYS News